{"url_path":"/sec/rlyb/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1739410/0001628280-26-034580-index.html","accession_number":"0001628280-26-034580","cik":"0001739410","ticker":"RLYB","issuer_name":"Rallybio Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1739410/0001628280-26-034580-index.html","primary_entity_key":"0001739410","primary_entity_name":"Rallybio Corp"},"word_count":418,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nExhibit\nNumberDescription\n\n2.1\n[Agreement and Plan of Merger and Reorganization among Rallybio Corporation, Farmington Merger Sub, Inc. and Candid Therapeutics, Inc., dated as of March 1, 2026 (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K (File No. 001-40693), filed with the SEC on March 2, 2026)](https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429dex21.htm)\n\n2.2\n[W](https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/d19625dex21.htm)[aiver, dated as of May 1, 2026, by and among Rallybio Corporation, Candid Therapeutics, Inc. and UCB S.A.](https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/d19625dex21.htm)\n\n10.1*†\n[Separation Agreement, dated March 31, 2026, by and between Rallybio Corporation and Steven Ryder, MD.](rlyb-20260331xex101.htm)\n\n31.1*\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rlyb-20260331xex311.htm)\n\n31.2*\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](rlyb-20260331xex312.htm)\n\n32.1*#\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rlyb-20260331xex321.htm)\n\n32.2*#\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](rlyb-20260331xex322.htm)\n\n101.INSInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCHInline XBRL Taxonomy Extension Schema Document\n\n101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LABInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\n_____________________\n\n*Filed herewith.\n\n#    The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates them by reference.\n\n† Indicates management contract or compensatory plan\n\n81\n\n[Table of Contents](#i15af2461236043f1aa58ea5a42666f82_7)\n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nRALLYBIO CORPORATION\n\nDate: May 13, 2026\nBy:/s/ Stephen Uden\n\nStephen Uden, M.D.\n\nChief Executive Officer, President and Director (Principal Executive Officer)\n\nDate: May 13, 2026\nBy:\n/s/ Jonathan I. Lieber\n\nJonathan I. Lieber\n\nChief Financial Officer and Treasurer (Principal Accounting and Financial Officer)\n\n82"}